SCHEMBL176922

SCHEMBL176922

Oc1ccc2c(C(F)(F)F)nn(C3CCCCO3)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 3/20 0.42
CYP4A11 Q02928 3/20 0.42
ESR1 P03372 2/20 0.41
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37
DGAT2 Q96PD7 1/20 0.35
ATR Q13535 3/20 0.34
ELANE P08246 2/20 0.34
GAA P10253 1/20 0.32
HTT P42858 1/20 0.32
RET P07949 1/20 0.32
RORC P51449 1/20 0.32
HTR3A P46098 1/20 0.31
HSD17B3 P37058 1/20 0.31
CNR2 P34972 1/20 0.31
CYP19A1 P11511 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP11B1 P15538 1/20 0.31
CYP11B2 P19099 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14800443 0.91 CYP4F2 (0.42) CYP4F2CYP4A11ESR1RXRARXRB
SCHEMBL177354 0.83 CYP11B2 (0.37) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL177579 0.79 DGAT2 (0.33) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL22890826 0.79 RXRA (0.37) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL14800689 0.79 RXRA (0.37) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL29872985 0.78 CYP4F2 (0.48) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL176897 0.77 CYP4F2 (0.40) CYP4F2CYP4A11ESR1RXRARXRB
SCHEMBL18370091 0.76 AR (0.36) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL18369828 0.76 RXRA (0.41) CYP4F2CYP4A11RXRARXRBRXRG
SCHEMBL2307876 0.75 CYP4F2 (0.39) CYP4F2CYP4A11ESR1RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2345644-A1 INDAZOLE COMPOUND Asahi Kasei Pharma Corporation (JP) 2011-07-20 EP claimed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US claimed
US-8008506-B2 Indazole compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-08-30 US disclosed
US-8008506-B2 Indazole compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-08-30 US disclosed
US-8008506-B2 Indazole compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-08-30 US disclosed
EP-2345644-A1 INDAZOLE COMPOUND Asahi Kasei Pharma Corporation (JP) 2011-07-20 EP disclosed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US disclosed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US disclosed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US disclosed
WO-2010041569-A1 INDAZOLE COMPOUND 旭化成ファーマ株式会社 (JP) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160256-A1 INDAZOLE COMPOUNDS GPR119, ADRB1, ADRA1A CYP4F2 394/4885CYP4A11 127/4885ESR1 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.